Figure 6

Type I Interferon modulates both, intestinal barrier function after allo-HSCT and allogeneic T cell priming by recipient APCs. The scheme shows two effects of IFN-I activation during conditioning therapy and allo-HSCT. (I) IFN-I reduces intestinal epithelial cell damage and protects intestinal barrier function during allo-HSCT and GVHD. (II) IFN-I limits the allogenicity of CD11c+ recipient APCs to prime allogeneic donor T cells.